FDA
-
-
-
-
-
-
-
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
-
-
-
-
-
-
-
Tenaya Therapeutics reports positive interim data from gene therapy trial
-
-
-
-
-
-
-
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
-
-
-
-
-
-
-
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
-
-
-
-
-
-
-
Tenaya Therapeutics (TNYA) Announces Updates on TN-201 Gene Therapy Program
-
-
-
-
-
-
-
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201
-
328,094 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

